Cochrane · systematic review · CD012157
Antidepressants for hip and knee osteoarthritis
Leaney, AA, Lyttle, JR, Segan, J, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 2 · 28.6%High 4 · 57.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antidepressant compared to placebo for osteoarthritis for Hip and Knee Osteoarthritis
Population: predominantly knee osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in pain from baseline (0‐ to 10‐point scale, 0 is no pain) at 8–16 weeks Antidepressant vs placebo | no estimate extracted | 9 studies · 2038 participants | High |
Responder rate: ≥ 50% reduction in 24‐hour mean pain Antidepressant vs placebo | RR 1.55 [1.32, 1.82] | 6 studies · 1904 participants | High |
Mean change in physical function from baseline (0–100 WOMAC Total score, 0 is best function) between 0 and 14 weeks Antidepressant vs placebo | no estimate extracted | 6 studies · 1909 participants | High |
Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks Antidepressant vs placebo | MD 0.04 [0.01, 0.07] | 3 studies · 815 participants | Moderate Downgraded: imprecision |
Proportion of participants who withdrew due to adverse events between 0 and 14 weeks Antidepressant vs placebo | RR 2.15 [1.56, 2.97] | 6 studies · 1977 participants | Moderate Downgraded: imprecision |
Total adverse events between 0 and 16 weeks Antidepressant vs placebo | RR 1.27 [1.15, 1.41] | 9 studies · 2101 participants | High |
Serious adverse events between 0 and 16 weeks Antidepressant vs placebo | RR 0.94 [0.46, 1.94] | 9 studies · 2101 participants | Low Downgraded: imprecision |